NCT00435448终止3 期
A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 480
- 试验地点
- 116
- 主要终点
- International prostate symptom score (I-PSS)
研究概览
简要总结
The purpose of this study is to evaluate the efficacy of lonidamine (50mg, 150mg) compared to placebo in subjects with symptomatic BPH.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 50 Years 至 80 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Capable of understanding the purpose and risks of the study and sign a statement of informed consent
- •Male 50-80 years of age
- •Presence of LUTS (lower urinary tract symptoms) for at least 3 months
- •Prostate volume measured by TRUS (transrectal ultrasound) > 30 cc
- •Qmax < 15 mL/sec when measured by uroflowmetry (minimum of 125 mL must be voided)
- •I-PSS (International prostate symptom score) > 12
- •PSA > 1.0 ng/mL
- •Must ensure and consent to use medically acceptable methods of contraception throughout the entire study with sexual partners of childbearing potential
- •Able to comply with the prescribed treatment protocol and evaluations
排除标准
- •Prior treatment for BPH with alpha-blockers and/or herbal supplements in the past 2 weeks (alpha-blockers and herbal supplements for the treatment of BPH are not allowed during the study). Prior treatment with 5-alpha-reductase inhibitors is allowed if discontinued at least 3 months prior to enrollment.
- •Prior surgery of the prostate (except biopsies; subject is eligible to enroll one month after full recovery from prostate biopsy.)
- •Current or past evidence of malignant disease of the prostate or prostatic intraepithelial neoplasia (for subjects with PSA between 4 - 10 ng/mL, prostate cancer must be ruled out to the satisfaction of the Principal Investigator. Subjects with PSA >10 ng/mL are excluded.)
- •Active urinary tract infections (UTI)
- •Active cardiac, renal or hepatic disease as evidenced by:
- •Serum creatinine > 1.8 mg/dL
- •ALT or AST > 2.5x the upper limit of normal at screen
- •History of active myocardial infarction,unstable cardiac arrhythmias or stroke within 6 months prior to screening
- •Uncontrolled congestive heart failure
- •Uncontrolled diabetes mellitus (fasting blood glucose > 200 mg/dL)
- •Use of systemic teriods for any reason (systemic steroid usage is not allowed during the study). Inhaled and/or topical steroids are allowed.
- •Concurrent participation or participation in an investigational drug study within the past 30 days prior to screening
- •Concomitant disease or condition that could interfere with the conduct of the study, or would in the opinion of the investigator,pose an unnaceptabele risk to the subject
结局指标
主要结局
International prostate symptom score (I-PSS)
次要结局
- Qmax on uroflowmetry
- Post micturitional residue
- Volume of the prostate
- PSA
研究者
研究点 (116)
Loading locations...
相似试验
终止
2 期
Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic HyperplasiaBenign Prostatic HyperplasiaNCT00237536Threshold Pharmaceuticals240
进行中（未招募）
3 期
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell TransplantDS Stage I Multiple MyelomaDS Stage II Multiple MyelomaDS Stage III Multiple MyelomaRefractory Multiple MyelomaSmoldering Multiple MyelomaNCT00114101National Cancer Institute (NCI)460
终止
2 期
A Study of Naldemedine in Participants Undergoing Surgeries That Include a Bowel Resection or Bowel TransectionPostoperative Gastrointestinal DysfunctionNCT04355169Shionogi2
撤回
3 期
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)Guillain-Barré SyndromeNCT05494619Hoffmann-La Roche
已完成
3 期
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] AbnormalityMyelodysplastic SyndromesNCT00179621Celgene Corporation205